Published on 9 Aug 2023 on Zacks via Yahoo Finance
Horizon (HZNP) Q2 Earnings Top, Krystexxa & Uplizna Boost Sales
Horizon Therapeutics plc HZNP delivered second-quarter 2023 adjusted earnings of $1.20 per share, which beat the Zacks Consensus Estimate of $1.12. The company reported adjusted earnings of $1.07 per share in the year-ago quarter.
Quarterly revenues of $945 million surged 8% year over year, owing mostly to the encouraging performance of its key drugs, Krystexxa, Tepezza and Uplizna, in the second quarter of 2023. Revenues surpassed the Zacks Consensus Estimate of $916 million.
Year-to-date, the shares of Horizon have declined 8.5% against the industry’s 13% decline.